In vivo opioid receptor heteromerization: Where do we stand?

British Journal of Pharmacology

Volumn 172, Issue 2, 2015, Pages 420-434

  Massotte, D ^a  

^a Institut des Neurosciences Cellulaires et Intégratives UPR3212   (France)

Author keywords

addiction; fluorescent knock in mice; GPCRs; heteromer; mood disorders; nociception; opioid receptors

Indexed keywords

CANNABINOID 1 RECEPTOR; CHEMOKINE RECEPTOR CXCR4; DELTA OPIATE RECEPTOR; G PROTEIN COUPLED RECEPTOR; GRP RECEPTOR; KAPPA OPIATE RECEPTOR; MESSENGER RNA; MOP1D RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; NOCICEPTIN RECEPTOR; OPIATE RECEPTOR; UNCLASSIFIED DRUG; NARCOTIC ANALGESIC AGENT;

BRAIN FUNCTION; BRAIN REGION; COMPUTER MODEL; DRUG TARGETING; ELECTRON MICROSCOPY; FLUORESCENCE ANALYSIS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HETEROMERIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION; IN VIVO STUDY; LIGAND BINDING; NERVE CELL; NONHUMAN; PROTEIN MODIFICATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DRUG DEVELOPMENT; HUMAN; METABOLISM; PROTEIN MULTIMERIZATION;

ANALGESICS, OPIOID; ANIMALS; DRUG DISCOVERY; HUMANS; PROTEIN MULTIMERIZATION; RECEPTORS, OPIOID;

EID: 84920169231     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12702     Document Type: Review

References (133)

1. Abdelhamid EE, Sultana M, Portoghese PS, Takemori AE, (1991). Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther 258: 299-303.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ligand-Gated Ion Channels. Br J Pharmacol 170: 1582-1606.
4. Altier C, Khosravani H, Evans RM, Hameed S, Peloquin JB, Vartian BA, et al. (2006). ORL1 receptor-mediated internalization of N-type calcium channels. Nat Neurosci 9: 31-40.
5. Ansonoff MA, Portoghese PS, Pintar JE, (2010). Consequences of opioid receptor mutation on actions of univalent and bivalent kappa and delta ligands. Psychopharmacology (Berl) 210: 161-168.
6. Aoki K, Kamioka Y, Matsuda M, (2013). Fluorescence resonance energy transfer imaging of cell signaling from in vitro to in vivo: basis of biosensor construction, live imaging, and image processing. Dev Growth Differ 55: 515-522.
7. Arttamangkul S, Quillinan N, Low MJ, von Zastrow M, Pintar J, Williams JT, (2008). Differential activation and trafficking of micro-opioid receptors in brain slices. Mol Pharmacol 74: 972-979.
8. Bailey CP, Connor M, (2005). Opioids: cellular mechanisms of tolerance and physical dependence. Curr Opin Pharmacol 5: 60-68.
9. Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U, (2007). Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal 19: 2304-2316.
10. Beedle AM, McRory JE, Poirot O, Doering CJ, Altier C, Barrere C, et al. (2004). Agonist-independent modulation of N-type calcium channels by ORL1 receptors. Nat Neurosci 7: 118-125.
11. Berg KA, Rowan MP, Gupta A, Sanchez TA, Silva M, Gomes I, et al. (2012). Allosteric interactions between delta and kappa opioid receptors in peripheral sensory neurons. Mol Pharmacol 81: 264-272.
12. Bhushan RG, Sharma SK, Xie Z, Daniels DJ, Portoghese PS, (2004). A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers. J Med Chem 47: 2969-2972.
13. Bibel M, Richter J, Schrenk K, Tucker KL, Staiger V, Korte M, et al. (2004). Differentiation of mouse embryonic stem cells into a defined neuronal lineage. Nat Neurosci 7: 1003-1009.
14. Birdsall NJ, (2010). Class A GPCR heterodimers: evidence from binding studies. Trends Pharmacol Sci 31: 499-508.
15. Borgland SL, Connor M, Osborne PB, Furness JB, Christie MJ, (2003). Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization, and endocytosis of mu-opioid receptors. J Biol Chem 278: 18776-18784.
16. Bruchas MR, Land BB, Chavkin C, (2010). The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res 1314: 44-55.
17. Burbassi S, Sengupta R, Meucci O, (2010). Alterations of CXCR4 function in mu-opioid receptor-deficient glia. Eur J Neurosci 32: 1278-1288.
18. Bushlin I, Gupta A, Stockton SD Jr, Miller LK, Devi LA, (2012). Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain. PLoS ONE 7: e49789.
19. Cahill CM, Holdridge SV, Morinville A, (2007). Trafficking of delta-opioid receptors and other G-protein-coupled receptors: implications for pain and analgesia. Trends Pharmacol Sci 28: 23-31.
20. Cahill CM, Morinville A, Lee MC, Vincent JP, Collier B, Beaudet A, (2001). Prolonged morphine treatment targets delta opioid receptors to neuronal plasma membranes and enhances delta-mediated antinociception. J Neurosci 21: 7598-7607.
21. Chabre M, Deterre P, Antonny B, (2009). The apparent cooperativity of some GPCRs does not necessarily imply dimerization. Trends Pharmacol Sci 30: 182-187.
22. Chakrabarti S, Liu NJ, Gintzler AR, (2010). Formation of mu-/kappa-opioid receptor heterodimer is sex-dependent and mediates female-specific opioid analgesia. Proc Natl Acad Sci U S A 107: 20115-20119.
23. Charbogne P, Kieffer BL, Befort K, (2014). 15 years of genetic approaches in vivo for addiction research: opioid receptor and peptide gene knockout in mouse models of drug abuse. Neuropharmacology 76 (Pt B): 204-217.
24. Cottet M, Faklaris O, Maurel D, Scholler P, Doumazane E, Trinquet E, et al. (2012). BRET and Time-resolved FRET strategy to study GPCR oligomerization: from cell lines toward native tissues. Front Endocrinol (Lausanne) 3: 92.
25. Coulon V, Audet M, Homburger V, Bockaert J, Fagni L, Bouvier M, et al. (2008). Subcellular imaging of dynamic protein interactions by bioluminescence resonance energy transfer. Biophys J 94: 1001-1009.
26. Cox BM, Christie MJ, Devi L, Toll L, Traynor JR, (2015). Challenges for opioid receptor nomenclature: IUPHAR Review 9. Br J Pharmacol 172: 317-323.
27. Daniels DJ, Kulkarni A, Xie Z, Bhushan RG, Portoghese PS, (2005a). A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes. J Med Chem 48: 1713-1716.
28. Daniels DJ, Lenard NR, Etienne CL, Law PY, Roerig SC, Portoghese PS, (2005b). Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci U S A 102: 19208-19213.
29. De A, Jasani A, Arora R, Gambhir SS, (2013). Evolution of BRET biosensors from live cell to tissue-scale imaging. Front Endocrinol (Lausanne) 4: 131.
30. Décaillot FM, Befort K, Filliol D, Yue SY, Walker P, Kieffer BL, (2003). Opioid receptor random mutagenesis reveals how a G protein-coupled receptor turns on. Nat Struct Biol 10: 629-636.
31. Décaillot FM, Rozenfeld R, Gupta A, Devi LA, (2008). Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4. Proc Natl Acad Sci U S A 105: 16045-16050.
32. Erbs E, Faget L, Scherrer G, Matifas A, Filliol D, Vonesch J-L, et al. (2014). A mu-delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical networks. Brain Struct Funct. doi: 10.1007/s00429-014-0717-9
33. Evans RM, You H, Hameed S, Altier C, Mezghrani A, Bourinet E, et al. (2010). Heterodimerization of ORL1 and opioid receptors and its consequences for N-type calcium channel regulation. J Biol Chem 285: 1032-1040.
34. Fan T, Varghese G, Nguyen T, Tse R, O'Dowd BF, George SR, (2005). A role for the distal carboxyl tails in generating the novel pharmacology and G protein activation profile of mu and delta opioid receptor hetero-oligomers. J Biol Chem 280: 38478-38488.
35. Feng Y, He X, Yang Y, Chao D, Lazarus LH, Xia Y, (2012). Current research on opioid receptor function. Curr Drug Targets 13: 230-246.
36. Ferre S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T, et al. (2009). Building a new conceptual framework for receptor heteromers. Nat Chem Biol 5: 131-134.
37. Filizola M, Devi LA, (2013). Grand opening of structure-guided design for novel opioids. Trends Pharmacol Sci 34: 6-12.
38. Filizola M, Olmea O, Weinstein H, (2002). Prediction of heterodimerization interfaces of G-protein coupled receptors with a new subtractive correlated mutation method. Protein Eng 15: 881-885.
39. Fonseca JM, Lambert NA, (2009). Instability of a class A GPCR oligomer interface. Mol Pharmacol 75: 1296-1299.
40. Gaveriaux-Ruff C, Kieffer BL, (2011). Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches. Behav Pharmacol 22: 405-414.
41. George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, et al. (2000). Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J Biol Chem 275: 26128-26135.
42. Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, Devi LA, (2004). A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci U S A 101: 5135-5139.
43. Gomes I, Ijzerman AP, Ye K, Maillet EL, Devi LA, (2011). G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol 79: 1044-1052.
44. Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, Devi LA, (2000). Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J Neurosci 20: 1-5.
45. Gomes I, Gupta A, Devi LA, (2013a). G-protein-coupled heteromers: regulation in disease. Methods Enzymol 521: 219-238.
46. Gomes I, Fujita W, Gupta A, Saldanha SA, Negri A, Pinello CE, et al. (2013b). Identification of a mu-delta opioid receptor heteromer-biased agonist with antinociceptive activity. Proc Natl Acad Sci U S A 110: 12072-12077.
47. Granier S, Manglik A, Kruse AC, Kobilka TS, Thian FS, Weis WI, et al. (2012). Structure of the delta-opioid receptor bound to naltrindole. Nature 485: 400-404.
48. Gupta A, Mulder J, Gomes I, Rozenfeld R, Bushlin I, Ong E, et al. (2010). Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal 3: ra54.
49. Haberstock-Debic H, Kim KA, Yu YJ, von Zastrow M, (2005). Morphine promotes rapid, arrestin-dependent endocytosis of mu-opioid receptors in striatal neurons. J Neurosci 25: 7847-7857.
50. Haberstock-Debic H, Wein M, Barrot M, Colago EE, Rahman Z, Neve RL, et al. (2003). Morphine acutely regulates opioid receptor trafficking selectively in dendrites of nucleus accumbens neurons. J Neurosci 23: 4324-4332.
51. Harrison C, van der Graaf PH, (2006). Current methods used to investigate G protein coupled receptor oligomerisation. J Pharmacol Toxicol Methods 54: 26-35.
52. Harvey JH, Long DH, England PM, Whistler JL, (2012). Tuned-affinity bivalent ligands for the characterization of opioid receptor heteromers. ACS Med Chem Lett 3: 640-644.
53. Hasbi A, Nguyen T, Fan T, Cheng R, Rashid A, Alijaniaram M, et al. (2007). Trafficking of preassembled opioid mu-delta heterooligomer-Gz signaling complexes to the plasma membrane: coregulation by agonists. Biochemistry 46: 12997-13009.
54. He SQ, Zhang ZN, Guan JS, Liu HR, Zhao B, Wang HB, et al. (2011). Facilitation of mu-opioid receptor activity by preventing delta-opioid receptor-mediated codegradation. Neuron 69: 120-131.
55. Heinisch S, Palma J, Kirby LG, (2011). Interactions between chemokine and mu-opioid receptors: anatomical findings and electrophysiological studies in the rat periaqueductal grey. Brain Behav Immun 25: 360-372.
56. Hojo M, Sudo Y, Ando Y, Minami K, Takada M, Matsubara T, et al. (2008). mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci 108: 308-319.
57. Illes P, Norenberg W, (1990). Blockade of alpha 2-adrenoceptors increases opioid mu-receptor-mediated inhibition of the firing rate of rat locus coeruleus neurones. Naunyn Schmiedebergs Arch Pharmacol 342: 490-496.
58. Ishikawa-Ankerhold HC, Ankerhold R, Drummen GP, (2012). Advanced fluorescence microscopy techniques-FRAP, FLIP, FLAP, FRET and FLIM. Molecules 17: 4047-4132.
59. Johnston JM, Aburi M, Provasi D, Bortolato A, Urizar E, Lambert NA, et al. (2011). Making structural sense of dimerization interfaces of delta opioid receptor homodimers. Biochemistry 50: 1682-1690.
60. Jones KA, Borowsky B, Tamm JA, Craig DA, Durkin MM, Dai M, et al. (1998). GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature 396: 674-679.
61. Jordan BA, Devi LA, (1999). G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399: 697-700.
62. Juhasz JR, Hasbi A, Rashid AJ, So CH, George SR, O'Dowd BF, (2008). Mu-opioid receptor heterooligomer formation with the dopamine D1 receptor as directly visualized in living cells. Eur J Pharmacol 581: 235-243.
63. Kabli N, Martin N, Fan T, Nguyen T, Hasbi A, Balboni G, et al. (2010). Agonists at the delta-opioid receptor modify the binding of micro-receptor agonists to the micro-delta receptor hetero-oligomer. Br J Pharmacol 161: 1122-1136.
64. Kabli N, Nguyen T, Balboni G, O'Dowd BF, George SR, (2013). Antidepressant-like and anxiolytic-like effects following activation of the mu-delta opioid receptor heteromer in the nucleus accumbens. Mol Psychiatry. doi: 10.1038/mp.2013.115.
65. Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Kang L, et al. (1996). Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 271: 19021-19024.
66. Kivell BM, Day DJ, McDonald FJ, Miller JH, (2004). Mu and delta opioid receptor immunoreactivity and mu receptor regulation in brainstem cells cultured from late fetal and early postnatal rats. Brain Res Dev Brain Res 149: 9-19.
67. Law PY, Erickson-Herbrandson LJ, Zha QQ, Solberg J, Chu J, Sarre A, et al. (2005). Heterodimerization of mu- and delta-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions. J Biol Chem 280: 11152-11164.
68. Le Merrer J, Becker JA, Befort K, Kieffer BL, (2009). Reward processing by the opioid system in the brain. Physiol Rev 89: 1379-1412.
69. Liu H, Zhang SC, (2011). Specification of neuronal and glial subtypes from human pluripotent stem cells. Cell Mol Life Sci 68: 3995-4008.
70. Liu NJ, von Gizycki H, Gintzler AR, (2007). Sexually dimorphic recruitment of spinal opioid analgesic pathways by the spinal application of morphine. J Pharmacol Exp Ther 322: 654-660.
71. Liu NJ, Chakrabarti S, Schnell S, Wessendorf M, Gintzler AR, (2011a). Spinal synthesis of estrogen and concomitant signaling by membrane estrogen receptors regulate spinal kappa- and mu-opioid receptor heterodimerization and female-specific spinal morphine antinociception. J Neurosci 31: 11836-11845.
72. Liu X, Kai M, Jin L, Wang R, (2009). Computational study of the heterodimerization between mu and delta receptors. J Comput Aided Mol Des 23: 321-332.
73. Liu XY, Liu ZC, Sun YG, Ross M, Kim S, Tsai FF, et al. (2011b). Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids. Cell 147: 447-458.
74. Lohse MJ, Nuber S, Hoffmann C, (2012). Fluorescence/bioluminescence resonance energy transfer techniques to study G-protein-coupled receptor activation and signaling. Pharmacol Rev 64: 299-336.
75. Lopez-Gimenez JF, Vilaro MT, Milligan G, (2008). Morphine desensitization, internalization, and down-regulation of the mu opioid receptor is facilitated by serotonin 5-hydroxytryptamine2A receptor coactivation. Mol Pharmacol 74: 1278-1291.
76. Lutz PE, Kieffer BL, (2012). Opioid receptors: distinct roles in mood disorders. Trends Neurosci 36: 195-206.
77. Lutz PE, Kieffer BL, (2013). The multiple facets of opioid receptor function: implications for addiction. Curr Opin Neurobiol 23: 473-479.
78. Manglik A, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM, Sunahara RK, et al. (2012). Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature 485: 321-326.
79. Massotte D, (2010). G protein-coupled receptor heterodimerization: a molecular determinant of neuronal activity. In:, Nogueira APS, (ed.). Neuroscience Research Progress Nogueira, Vol. 2. Novapublishers: Hauppage, NY.
80. Maurel D, Comps-Agrar L, Brock C, Rives ML, Bourrier E, Ayoub MA, et al. (2008). Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization. Nat Methods 5: 561-567.
81. Milan-Lobo L, Enquist J, van Rijn RM, Whistler JL, (2013). Anti-analgesic effect of the mu/delta opioid receptor heteromer revealed by ligand-biased antagonism. PLoS ONE 8: e58362.
82. Milan-Lobo L, Whistler JL, (2011). Heteromerization of the mu- and delta-opioid receptors produces ligand-biased antagonism and alters mu-receptor trafficking. J Pharmacol Exp Ther 337: 868-875.
83. Molinari P, Ambrosio C, Riitano D, Sbraccia M, Gro MC, Costa T, (2003). Promiscuous coupling at receptor-G alpha fusion proteins. The receptor of one covalent complex interacts with the alpha-subunit of another. J Biol Chem 278: 15778-15788.
84. Morinville A, Cahill CM, Esdaile MJ, Aibak H, Collier B, Kieffer BL, et al. (2003). Regulation of delta-opioid receptor trafficking via mu-opioid receptor stimulation: evidence from mu-opioid receptor knock-out mice. J Neurosci 23: 4888-4898.
85. Nadal X, La Porta C, Andreea Bura S, Maldonado R, (2013). Involvement of the opioid and cannabinoid systems in pain control: new insights from knockout studies. Eur J Pharmacol 716: 142-157.
86. Nitsche JF, Schuller AG, King MA, Zengh M, Pasternak GW, Pintar JE, (2002). Genetic dissociation of opiate tolerance and physical dependence in delta-opioid receptor-1 and preproenkephalin knock-out mice. J Neurosci 22: 10906-10913.
87. Oldfield S, Braksator E, Rodriguez-Martin I, Bailey CP, Donaldson LF, Henderson G, et al. (2008). C-terminal splice variants of the mu-opioid receptor: existence, distribution and functional characteristics. J Neurochem 104: 937-945.
88. Parenty G, Appelbe S, Milligan G, (2008). CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer. Biochem J 412: 245-256.
89. Patel JP, Sengupta R, Bardi G, Khan MZ, Mullen-Przeworski A, Meucci O, (2006). Modulation of neuronal CXCR4 by the micro-opioid agonist DAMGO. J Neurovirol 12: 492-500.
90. Peljto M, Wichterle H, (2011). Programming embryonic stem cells to neuronal subtypes. Curr Opin Neurobiol 21: 43-51.
91. Pello OM, Martinez-Munoz L, Parrillas V, Serrano A, Rodriguez-Frade JM, Toro MJ, et al. (2008). Ligand stabilization of CXCR4/delta-opioid receptor heterodimers reveals a mechanism for immune response regulation. Eur J Immunol 38: 537-549.
92. Pin JP, Neubig R, Bouvier M, Devi L, Filizola M, Javitch JA, et al. (2007). International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev 59: 5-13.
93. Plachta N, Bibel M, Tucker KL, Barde YA, (2004). Developmental potential of defined neural progenitors derived from mouse embryonic stem cells. Development 131: 5449-5456.
94. Pradhan AA, Becker JA, Scherrer G, Tryoen-Toth P, Filliol D, Matifas A, et al. (2009). In vivo delta opioid receptor internalization controls behavioral effects of agonists. PLoS ONE 4: e5425.
95. Pradhan AA, Befort K, Nozaki C, Gaveriaux-Ruff C, Kieffer BL, (2011). The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci 32: 581-590.
96. Pradhan AA, Walwyn W, Nozaki C, Filliol D, Erbs E, Matifas A, et al. (2010). Ligand-directed trafficking of the delta-opioid receptor in vivo: two paths toward analgesic tolerance. J Neurosci 30: 16459-16468.
97. Raehal KM, Schmid CL, Groer CE, Bohn LM, (2011). Functional selectivity at the mu-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev 63: 1001-1019.
98. Ramsay D, Kellett E, McVey M, Rees S, Milligan G, (2002). Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. Biochem J 365: 429-440.
99. Riedl MS, Schnell SA, Overland AC, Chabot-Dore AJ, Taylor AM, Ribeiro-da-Silva A, et al. (2009). Coexpression of alpha 2A-adrenergic and delta-opioid receptors in substance P-containing terminals in rat dorsal horn. J Comp Neurol 513: 385-398.
100. van Rijn RM, Whistler JL, (2009). The delta(1) opioid receptor is a heterodimer that opposes the actions of the delta(2) receptor on alcohol intake. Biol Psychiatry 66: 777-784.
101. van Rijn RM, Brissett DI, Whistler JL, (2010a). Dual efficacy of delta opioid receptor selective ligands for ethanol drinking and anxiety. J Pharmacol Exp Ther 335: 133-139.
102. van Rijn RM, Whistler JL, Waldhoer M, (2010b). Opioid-receptor-heteromer-specific trafficking and pharmacology. Curr Opin Pharmacol 10: 73-79.
103. Rios C, Gomes I, Devi LA, (2006). mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148: 387-395.
104. Rodriguez JJ, Mackie K, Pickel VM, (2001). Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 21: 823-833.
105. Rodriguez-Munoz M, Sanchez-Blazquez P, Vicente-Sanchez A, Berrocoso E, Garzon J, (2012). The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control. Neuropsychopharmacology 37: 338-349.
106. Rondard P, Goudet C, Kniazeff J, Pin JP, Prezeau L, (2011). The complexity of their activation mechanism opens new possibilities for the modulation of mGlu and GABAB class C G protein-coupled receptors. Neuropharmacology 60: 82-92.
107. Rosenbaum DM, Rasmussen SG, Kobilka BK, (2009). The structure and function of G-protein-coupled receptors. Nature 459: 356-363.
108. Rozenfeld R, Devi LA, (2007). Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. FASEB J 21: 2455-2465.
109. Rozenfeld R, Devi LA, (2011). Exploring a role for heteromerization in GPCR signalling specificity. Biochem J 433: 11-18.
110. Rozenfeld R, Bushlin I, Gomes I, Tzavaras N, Gupta A, Neves S, et al. (2012). Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons. PLoS ONE 7: e29239.
111. Salim K, Fenton T, Bacha J, Urien-Rodriguez H, Bonnert T, Skynner HA, et al. (2002). Oligomerization of G-protein-coupled receptors shown by selective co-immunoprecipitation. J Biol Chem 277: 15482-15485.
112. Scherrer G, Befort K, Contet C, Becker J, Matifas A, Kieffer BL, (2004). The delta agonists DPDPE and deltorphin II recruit predominantly mu receptors to produce thermal analgesia: a parallel study of mu, delta and combinatorial opioid receptor knockout mice. Eur J Neurosci 19: 2239-2248.
113. Scherrer G, Tryoen-Toth P, Filliol D, Matifas A, Laustriat D, Cao YQ, et al. (2006). Knockin mice expressing fluorescent delta-opioid receptors uncover G protein-coupled receptor dynamics in vivo. Proc Natl Acad Sci U S A 103: 9691-9696.
114. Schiller PW, (2010). Bi- or multifunctional opioid peptide drugs. Life Sci 86: 598-603.
115. Sengupta R, Burbassi S, Shimizu S, Cappello S, Vallee RB, Rubin JB, et al. (2009). Morphine increases brain levels of ferritin heavy chain leading to inhibition of CXCR4-mediated survival signaling in neurons. J Neurosci 29: 2534-2544.
116. Sleister HM, Rao AG, (2002). Subtractive immunization: a tool for the generation of discriminatory antibodies to proteins of similar sequence. J Immunol Methods 261: 213-220.
117. Snook LA, Milligan G, Kieffer BL, Massotte D, (2006). Mu-delta opioid receptor functional interaction: insight using receptor-G protein fusions. J Pharmacol Exp Ther 318: 683-690.
118. Snook LA, Milligan G, Kieffer BL, Massotte D, (2008). Co-expression of mu and delta opioid receptors as receptor-G protein fusions enhances both mu and delta signalling via distinct mechanisms. J Neurochem 105: 865-873.
119. Spanagel R, Almeida OF, Shippenberg TS, (1994). Evidence that nor-binaltorphimine can function as an antagonist at multiple opioid receptor subtypes. Eur J Pharmacol 264: 157-162.
120. Stockton SD, Jr,., Devi LA, (2012). Functional relevance of mu-delta opioid receptor heteromerization: a role in novel signaling and implications for the treatment of addiction disorders: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend 121: 167-172.
121. Stone LS, Wilcox GL, (2004). Alpha-2-adrenergic and opioid receptor additivity in rat locus coeruleus neurons. Neurosci Lett 361: 265-268.
122. Thompson AA, Liu W, Chun E, Katritch V, Wu H, Vardy E, et al. (2012). Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature 485: 395-399.
123. Waldhoer M, Fong J, Jones RM, Lunzer MM, Sharma SK, Kostenis E, et al. (2005). A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci U S A 102: 9050-9055.
124. Walwyn W, John S, Maga M, Evans CJ, Hales TG, (2009). Delta receptors are required for full inhibitory coupling of mu-receptors to voltage-dependent Ca(2+) channels in dorsal root ganglion neurons. Mol Pharmacol 76: 134-143.
125. Walwyn WM, Miotto KA, Evans CJ, (2010). Opioid pharmaceuticals and addiction: the issues, and research directions seeking solutions. Drug Alcohol Depend 108: 156-165.
126. Wang HL, Hsu CY, Huang PC, Kuo YL, Li AH, Yeh TH, et al. (2005). Heterodimerization of opioid receptor-like 1 and mu-opioid receptors impairs the potency of micro receptor agonist. J Neurochem 92: 1285-1294.
127. Wu H, Wacker D, Mileni M, Katritch V, Han GW, Vardy E, et al. (2012). Structure of the human kappa-opioid receptor in complex with JDTic. Nature 485: 327-332.
128. Xie WY, He Y, Yang YR, Li YF, Kang K, Xing BM, et al. (2009). Disruption of Cdk5-associated phosphorylation of residue threonine-161 of the delta-opioid receptor: impaired receptor function and attenuated morphine antinociceptive tolerance. J Neurosci 29: 3551-3564.
129. Xie Z, Bhushan RG, Daniels DJ, Portoghese PS, (2005). Interaction of bivalent ligand KDN21 with heterodimeric delta-kappa opioid receptors in human embryonic kidney 293 cells. Mol Pharmacol 68: 1079-1086.
130. Yekkirala AS, Lunzer MM, McCurdy CR, Powers MD, Kalyuzhny AE, Roerig SC, et al. (2011). N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of mu/kappa-opioid heteromers. Proc Natl Acad Sci U S A 108: 5098-5103.
131. von Zastrow M, (2010). Regulation of opioid receptors by endocytic membrane traffic: mechanisms and translational implications. Drug Alcohol Depend 108: 166-171.
132. Zhang X, Bao L, Guan JS, (2006). Role of delivery and trafficking of delta-opioid peptide receptors in opioid analgesia and tolerance. Trends Pharmacol Sci 27: 324-329.
133. Zhu Y, King MA, Schuller AG, Nitsche JF, Reidl M, Elde RP, et al. (1999). Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 24: 243-252.